Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Study Overview
=================
Brief Summary
-----------------
Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.

Detailed Description
-----------------
Main Study: Approximately 16 subjects will participate in the BPX-501 main study. The treatment consists of three courses of BPX-501 T cell infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0; DL2 on Days 30 and 60. Two doses of rimiducid (AP1903) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion. A 0.1mg/kg initial dose of rimiducid which has demonstrated the ability to induce >50% BPX-501 T cell eradication in preclinical animal models will first be administered in the event of uncontrollable aGvHD. If there is no response to this dose within 24hrs + 12hrs a second dose of 0.4 mg/kg (which has been reported to induce T cell eradication of > 90%) will be administered. If there is no measurable GvHD response to the initial dose of 0.1 mg/kg rimiducid in 2 subjects, the starting dose of rimiducid will be 0.4 mg/kg for all subsequent subjects. Rimiducid (AP1903) Optional PK Sub-Study: Approximately 12 subjects will be recruited to participate in the optional Rimiducid (AP1903) PK sub-study. Subjects will be assigned to one of two arms and receive either 0.04mg/kg or 0.4mg/kg of Rimiducid (AP1903). Each arm will have a target enrollment of 6 subjects. Arm 1: 0.04mg/kg Rimiducid (AP1903), 6 subjects; Arm 2: 0.4mg/kg Rimiducid (AP1903), 6 subjects. Rimiducid PK samples and ECG data will be collected at Pre-dose (0 hour), 30 minutes, 2 hours and 8 hours following the initiation of rimiducid (AP1903) infusion. Efforts shall be made to enroll at least one subject from each age subset into the PK sub-study: infants and toddlers (12 months to 23 months); children (2-11 years); and adolescents (12-18 years).

Official Title
-----------------
A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

Conditions
-----------------
Hematologic Malignancy

Intervention / Treatment
-----------------
* Biological: BPX-501 T cells
* Drug: rimiducid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged < 18 Clinical diagnosis of one of the following pediatric hematological malignancies: High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]) in any CR Acute Leukemia that is minimal residual disease (MRD) positive at > 1copy per 1 x 10,000 reference copies pre-HSCT Myelodysplastic Syndrome (MDS) Hodgkin or Non-Hodgkin lymphomas Other high-risk hematological malignancy in CR eligible for stem cell transplantation per institutional standard Patients with a hematological malignancy who have received a prior allogeneic HSCT Patients with on-treatment relapse of AML within 6 months of initial CR Patients relapsing within 6 months of initial diagnosis of hematological malignancy. Planned or previous treatment of hematological malignancy with one of the following: Matched related HSCT Mismatched related HSCT For patients who have received a transplant, occurrence of one of the following > 30 days post-HSCT: Minimal residual disease (MRD) positive at > 1 copy per 1 x 10,000 reference copies post-HSCT Decreasing donor chimerism detected on two bone marrow biopsies or peripheral blood analyses at a > 7-day interval Recurrent disease Life expectancy >10 weeks; Signed donor and patient/guardian informed consent; For mismatched related donor recipients, a minimum genotypic identical match of 5/10 is required, as determined by high resolution typing, at least one allele of each of the following genetic loci must be matched: HLA-A, HLA-B, HLA-C, HLA- DRB1, and HLA-DQB1. Performance status: Karnofsky/Lansky score > 70%. Adequate organ function as measured by: High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]) in any CR High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid leukemia [AML]) in any CR Hepatic: direct bilirubin ≤ 3x ULN, or AST/ALT ≤ 5x ULN. Bone marrow; > 25% donor T cell chimerism ANC >1 x 10^9/L. Cardiac: LVEF at rest >45%. Pulmonary: FEV 1, FVC, DLCO (diffusion capacity for CO) > 50% predicted (corrected for hemoglobin); for children who are unable to perform pulmonary function tests due to age or developmental ability, there must be no evidence of dyspnea or no need for supplemental oxygen as evidenced by 02 saturation ≥ 92% on room air. Hepatic: direct bilirubin ≤ 3x ULN, or AST/ALT ≤ 5x ULN. Renal: creatinine clearance ≤ 2x of ULN for age Exclusion Criteria: ≥ Grade II acute GVHD or moderate to severe chronic GVHD due to a previous allograft at the time of screening; Active CNS involvement by malignant cells (< 2 months prior to time of consent); Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings). Positive HIV serology or viral RNA; Pregnancy (positive serum βHCG test) or breast-feeding female; Patients of reproductive age unwilling to use effective forms of birth control or abstinence for a year after BPX-501 T cell infusion.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BPX-501 T cells and rimiducid<br>All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT). Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion. | Biological: BPX-501 T cells<br>* Biological: T cells transduced with CaspaCIDe® safety switch<br>* Other names: rivogenlecleucel;Drug: rimiducid<br>* administered to eliminate BPX-501 cells in the event of GVHD<br>* Other names: AP1903;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BPX-501 Safety | Incidence of treatment emergent adverse events of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in pediatric subjects with hematologic malignancies | Month 24 | 
| Mean plasma concentration | Measure plasma concentrations of rimiducid (AP1903) at two doses (Arm 1: 0.04mg/kg; Arm 2: 0.4mg/kg) in pediatric subjects, during and after a 2-hour infusion | pre-dose, 30 min, 2 hours and 8 hours after start of infusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Measure overall survival rates after BPX-501 infusion | Month 24 | 
| Response Rate | Assess response rates after BPX-501 infusion | Month 24 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
leukemia, myelodysplastic syndrome, lymphoma, minimal residual disease, BPX-501, AP1903, rimiducid